Efficacy of multimodality therapy for patients with large-sized locally advanced breast cancer - a retrospective analysis of 17 cases

The objective of this study was to explore the clinical significance of multimodality therapy for huge-sized locally advanced breast cancer (LABC) in a retrospective analysis of 17 patients with large-sized locally advanced breast cancer. The mean tumor size was 11.5×10.1× cm. Among these 17 patients, three (17.6%) cases developed clinical evidence of distant metastases (liver, lung, bone, etc.), ten cases (58.8%) had skin ulcers, and discharges with a peculiar smell. The patients underwent TEC/AT chemotherapy, interventional therapy, and Ad-p53 gene therapy. All treatments were well-tolerated and 15 (88.2%) cases of the patient underwent standard or modified radical mastectomy successfully. The other two patients, who di not undergo surgical treatment because of metastases and other reasons, were treated with endocrine therapy. Until now, the average survival time has reached 31.5 months. In treating large-sized locally advanced breast cancer, multimodal therapies are able to diminish the burthen of the tumor, lower the clinical stage, and increase resection rate of cancer, thus improving survival rates and quality of life for patients.

LABC; Multimodality therapy; Ad-p53 gene therapy; Interventional therapy.

[1] Tryfonidis K., Senkus E., Cardoso M.J., Cardoso F.: “Management of locally advanced breast cancer—perspectives and future directions American Joint Commission on Cancer”. Nat. Rev. Clin. Oncol., 2015, 12, 147.

[2] National Comprehensive Cancer Network (NCCN): “NCCN Clinical Practice Guidelines in Oncology: Breast Cancer”. Fort Washington, PA: NCCN; 2015. Ver. 3.2015. Available at: http://www.nccn. org/professionals/physician_gls/pdf/breast.pdf

[3] Shimamoto H., Takizawa K., Ogawa Y., Yoshimatsu M., Yagihashi K., Okazaki H., et al.: “Clinical efficacy and value of redistributed subclavian arterial infusion chemotherapy for locally advanced breast cancer”. Jpn. J. Radiol., 2011, 29, 236.

[4] Santoro G., Avossa M., Della Corte M.: “Radiofrequency thermoablation in locally advanced breast cancer”. Breast, 2012, 21, 601.

[5] Debled M., MacGrogan G., Breton-Callu C., Ferron S., Hurtevent G., Fournier M., et al.: “ Surgery following NAC for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude”. Eur. J. Cancer, 2015, 51, 697.

[6] Emiroglu M., Sert I., Karaali C., Aksoy S.O., Ugurlu L., Aydın C.: “The effectiveness of simultaneous oncoplastic breast surgery in patients with locally advanced breast cancer”. Breast Cancer, 2016, 23, 463.

[7] Xie Y.S., Zhang Y.H., Liu S.P., Liu S.Q., Peng C.W., Wu L., et al.: “Synergistic gastric cancer inhibition by chemogenetherapy with recombinant human adenovirus p53 and epirubicin: an in vitro and in vivo study”. Oncol. Rep., 2010, 24, 1613.

[8] Nakajima S., Niizeki H., Tada M., Nakagawa K., Kondo S., Okada F., Kobayashi M.: Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231”. Oncol. Rep., 2009, 22, 143.

[9] Qi X., Chang Z., Song J., Gao G., Shen Z.: “Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin”. Anticancer Drugs, 2011, 22, 556.

[10] Simos D., Clemons M., Ginsburg O.M., Jacobs C.: “Definition and consequences of locally advanced breast cancer”. Curr. Opin. Support Palliat. Care, 2014, 8, 33.

[11] Perez E.A., Foo M.L., Fulmer J.T.: “Management of locally advanced breast cancer”. Oncology (Williston Park), 1997, 11, 9.

[12] Fei F., Messina C., Slaets L., Chakiba C., Cameron D., Bogaerts J., Bonnefoi H.: “Tumor size is the only predictive factor of distant recurrence after pathological complete response to NAC in patients with large operable or locally advanced breast cancers: A sub-study of EORTC 10994/BIG 1-00 phase III trial”. Eur. J. Cancer, 2015, 51, 301.

[13] Chan A., Willsher P.C., Hastrich D.J., Anderson J., Barham T., Latham B., et al.: “Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancer”. Asia Pac, J. Clin. Oncol., 2012, 8, 62.

[14] Ooe A., Takahara S., Sumiyoshi K., Yamamoto H., Kawai J., Shiba E.: “Relationship between intrinsic subtypes and tumor responses to NAC in patients with locally advanced breast cancer”. Breast Dis., 2012, 34, 9.

[15] Kaufman P.A., Awada A., Twelves C., Yelle L., Perez E.A., Velikova G., et al.: “Phase III Open-Label Randomized Study of Eribulin esylate Versus Capecitabine in Patients With Locally advanced or Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane”. J. Clin. Oncol., 2015, 33, 594.

[16] Cristofanilli M., Krishnamurthy S., Guerra L., Broglio K., Arun B., Booser D.J., et al.: “A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach”. Cancer, 2006, 107, 935.

[17] He S.Z., Qi X.D., Zhang X.M., Wang Y.: “Experimental study of adenovirus-mediated p53 gene on the reversal of multidrug resistance in breast cancer”. Zhonghua Yi Xue Za Zhi, 2007, 87, 2935.

[18] Wang X., Gan C., Li H., Wei Y., Zhu D., Yang G., et al.: “Main complications and results of treatment with intra-arterial infusion chemotherapy through the subclavian and thoracic arteries for locally advanced breast cancer”. Mol. Clin. Oncol., 2013, 1, 745.

[19] Jin H.Y., He W., Liu Q., Wang X.F., Liu Y.F., Wei Z.X.: “Efficacy of intra-arterial NAC through the superior epigastric artery in the treatment of locally advanced triple negative breast cancer”. Neoplasma, 2016, 63, 607.

[20] Wink C.J., Woensdregt K., Nieuwenhuijzen G.A., van der Sangen M.J., Hutschemaekers S., Roukema J.A., et al.: “Hormone Treatment without Surgery for Patients Aged 75 Years or Older with Operable Breast Cancer”. Ann. Surg. Oncol., 2012, 19, 1185.

[21] Nomiya T., Akamatsu H., Harada M., Ota I., Hagiwara Y., Ichikawa M., et al.: “Modified simultaneous integrated boost radiotherapy for unresectable locally advanced breast cancer: preliminary results of a prospective clinical trial”. Clin. Breast Cancer, 2015, 15, 161.